Search results
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises three syndromes, all with frequent respiratory manifestations. Studies indicate that ANCA specificity is more important for prognosis, relapse risk, response to therapy and outcomes than the specific diagnosis.
This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases. 1.
Apr 8, 2021 · Significant progress has been made in the treatment of ANCA-associated vasculitides (AAV), notably in granulomatosis with polyangiitis and microscopic polyangiitis. Over the past few years, many innovative studies have changed the way we now induce and maintain remission in AAV; achieving remission while limiting treatment toxicity is the key.
In general, treatment for ANCA vasculitis involves 2 parts. The first part is called induction therapy , which is aimed at trying to get the disease controlled and into remission. Once the disease goes into remission, the second part of treatment is called maintenance therapy .
This includes new evidence on using lower doses of corticosteroids like rituximab and complement inhibition to treat ANCA vasculitis, as well as the use of avacopan as an alternative to glucocorticoids.
Evaluate benefits and harms of reduced starting doses of GC (eg, 0.5 mg/day) compared with standard starting doses (1 mg/kg/day) in patients with different ANCA subtypes, severity stages and risk factors for adverse outcomes. Investigate optimal duration of therapy with GC.
This Review focuses on diagnosis and treatment of PR3-ANCA-associated vasculitis and MPO-ANCA-associated vasculitis, and on the disease phenotypes of granulomatosis with polyangiitis and microscopic polyangiitis.
We would like to show you a description here but the site won’t allow us.
Apr 1, 2021 · From a therapeutic perspective, multiple targets have been identified for currently approved therapies and/or future directions, as treatment of ANCA-associated vasculitis becomes more precise and personalized, aiming to minimize the risks of therapy.
Aug 1, 2013 · In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of...
